MX2021012011A - Agentes anti-ccr5 y metodos de tratamiento que bloquean la metastasis del cancer o intensifican la muerte celular inducida por quimioterapia da?ina al adn. - Google Patents

Agentes anti-ccr5 y metodos de tratamiento que bloquean la metastasis del cancer o intensifican la muerte celular inducida por quimioterapia da?ina al adn.

Info

Publication number
MX2021012011A
MX2021012011A MX2021012011A MX2021012011A MX2021012011A MX 2021012011 A MX2021012011 A MX 2021012011A MX 2021012011 A MX2021012011 A MX 2021012011A MX 2021012011 A MX2021012011 A MX 2021012011A MX 2021012011 A MX2021012011 A MX 2021012011A
Authority
MX
Mexico
Prior art keywords
ccr5
dna damaging
agents
cancer
treatment
Prior art date
Application number
MX2021012011A
Other languages
English (en)
Inventor
Richard G Pestell
Scott Kelly
Original Assignee
Cytodyn Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytodyn Inc filed Critical Cytodyn Inc
Publication of MX2021012011A publication Critical patent/MX2021012011A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/812—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente descripción se refiere al uso de agentes dañinos al ADN y leronlimab (PRO 140), u otros agentes anti-CCR5, para tratar o prevenir las metástasis del cáncer e intensificar la capacidad de eliminación celular de los agentes dañinos al ADN al dirigirse con acción selectiva al receptor CCR5. La presente descripción se refiere al uso de agentes dañinos al ADN y leronlimab (PRO 140), u otros agentes anti-CCR5, para tratar o prevenir las metástasis del cáncer y reducir las células tumorales séricas (CTC) o supuestas células tumorales metastásicas en la sangre periférica después del tratamiento, reducir la expresión de CCR5 en células asociadas al cáncer después del tratamiento, disminuir el volumen del tamaño del tumor después del tratamiento. La presente descripción se puede utilizar para el tratamiento o prevención de cáncer en sujetos y, particularmente, sujetos con cáncer CCR5+ metastásico.
MX2021012011A 2019-04-01 2020-04-01 Agentes anti-ccr5 y metodos de tratamiento que bloquean la metastasis del cancer o intensifican la muerte celular inducida por quimioterapia da?ina al adn. MX2021012011A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962827729P 2019-04-01 2019-04-01
PCT/US2020/026253 WO2020206026A1 (en) 2019-04-01 2020-04-01 Anti-ccr5 agents and methods of treatment that block cancer metastasis or enhance cell death induced by dna damaging chemotherapy

Publications (1)

Publication Number Publication Date
MX2021012011A true MX2021012011A (es) 2021-10-22

Family

ID=72667128

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012011A MX2021012011A (es) 2019-04-01 2020-04-01 Agentes anti-ccr5 y metodos de tratamiento que bloquean la metastasis del cancer o intensifican la muerte celular inducida por quimioterapia da?ina al adn.

Country Status (9)

Country Link
US (1) US20220162327A1 (es)
EP (1) EP3947431A4 (es)
JP (1) JP2022527966A (es)
CN (1) CN114729023A (es)
AU (1) AU2020254692A1 (es)
BR (1) BR112021019405A2 (es)
CA (1) CA3134836A1 (es)
MX (1) MX2021012011A (es)
WO (1) WO2020206026A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021207851A1 (en) * 2020-01-13 2022-07-14 Cytodyn Inc. CCR5 binding agent for treatment of CCR5 positive metastatic cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2647282A1 (en) * 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
EP2476441A1 (en) * 2011-01-13 2012-07-18 Universitat Autònoma De Barcelona Methods and reagents for efficient and targeted delivery of therapeutic molecules to CXCR4 cells
CN107847514A (zh) * 2015-06-23 2018-03-27 西托戴恩股份有限公司 炎症、癌症、自身免疫和其它病症中ccl5配体结合ccr5受体的抑制作用和ccr5/ccl5轴信号传导的改变
KR20210016398A (ko) * 2018-05-28 2021-02-15 오리온 바이오테크놀로지 스윗졀랜드 에스아에흐엘 암 치료에 사용하기 위한 ccr5 억제제
AU2021207851A1 (en) * 2020-01-13 2022-07-14 Cytodyn Inc. CCR5 binding agent for treatment of CCR5 positive metastatic cancer

Also Published As

Publication number Publication date
EP3947431A4 (en) 2022-12-28
CN114729023A (zh) 2022-07-08
AU2020254692A1 (en) 2021-10-28
WO2020206026A1 (en) 2020-10-08
EP3947431A1 (en) 2022-02-09
CA3134836A1 (en) 2020-10-08
US20220162327A1 (en) 2022-05-26
BR112021019405A2 (pt) 2021-11-30
JP2022527966A (ja) 2022-06-07

Similar Documents

Publication Publication Date Title
WO2018068008A8 (en) T cells expressing membrane-anchored il-12 for the treatment of cancer
AU2018341571A8 (en) Therapeutic methods relating to HSP90 inhibitors
EA201692200A1 (ru) Комбинация леналидомида и полипептидной конструкции и ее применение
MX2021008605A (es) Arn terapéutico y anticuerpos anti-pd1 para canceres de tumor sólido en estadio avanzado.
MY180365A (en) Markers of tumor cell response to anti-cancer therapy
TN2016000553A1 (en) Methods and compositions for treating ulcers
CY1114006T1 (el) Τοπικα σκευασματα συνενζυμου q10 και μεθοδοι χρησης
ES2422605T3 (es) Anticuerpo contra klotho-beta para utilizar en el tratamiento de tumores, cáncer o trastornos proliferativos celulares
MX2021006238A (es) Metodos para tratamiento que usan terapia celular adoptiva.
IL178042A0 (en) Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
EA202091539A1 (ru) Комбинированная терапия против злокачественной опухоли антагонистом iap и молекулой против pd-1
MX2018007933A (es) Metodo de tratamiento de mamifero, incluido el ser humano, contra cancer usando agotamiento de metionina y asparagina.
EA202191257A1 (ru) Противораковая терапия на основе иммуноцитов, связывающих liv1
EA200970607A1 (ru) Универсальная вакцина из опухолевых клеток для противораковой терапии и профилактического использования
MX2021005646A (es) Métodos de tratamiento de cáncer con agentes de unión a tubulina.
MX2009010269A (es) Metodos de tratamiento del cancer mediante administracion de combinaciones de interleucina-18 humana.
MX2021002241A (es) Uso de linfocitos infiltrantes de tumor para tratar pacientes con carcinoma de pulmón de células no pequeñas (nsclc) refractario al anticuerpo anti muerte programada 1 (pd-1).
MX2021006244A (es) Metodos de dosificacion y tratamiento de canceres de celulas b en terapia celular adoptiva.
ATE478076T1 (de) Azaxanthonen zur behandlung von tumoren
MX2021012011A (es) Agentes anti-ccr5 y metodos de tratamiento que bloquean la metastasis del cancer o intensifican la muerte celular inducida por quimioterapia da?ina al adn.
MX2021008604A (es) Arn terapeutico para tumores solidos cancerigenos en etapa avanzada.
MX2021003734A (es) Métodos de tratamiento del linfoma de linfocitos t periférico mediante terapia con conjugado fármaco-anticuerpo anti-cd30.
MX2021001252A (es) Partículas de modificación inmunitaria para el tratamiento del cáncer.
EA202191273A1 (ru) Применение тивозаниба для лечения субъектов с рефрактерным раком